Phase 2 Parkinson Disease Clinical Trials
44 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 44 trials
Recruiting
Phase 2
A Trial to Test the Use of Dapansutrile, an Anti-inflammatory Medication, in People With Parkinson's Disease
Parkinson Disease
Cambridge University Hospitals NHS Foundation Trust36 enrolled1 locationNCT07157735
Recruiting
Phase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Parkinson DiseaseParkinsonParkinson Disease, Idiopathic+2 more
Neuron23 Inc.150 enrolled70 locationsNCT06680830
Recruiting
Phase 2
D-SPARK: A Clinical Trial of D-Serine for Modifying Parkinson's Disease Progression
Parkinson's DiseaseParkinson Disease (PD)
Haukeland University Hospital100 enrolled11 locationsNCT07312110
Recruiting
Phase 2
Psilocybin Therapy for Depression in Parkinson's Disease
DepressionParkinson Disease
Joshua Woolley, MD, PhD60 enrolled1 locationNCT06455293
Recruiting
Phase 2
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
Parkinson Disease
Gateway Institute for Brain Research56 enrolled3 locationsNCT05266417
Recruiting
Phase 2
Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease
Parkinson Disease
Hillhurst Biopharmaceuticals, Inc.36 enrolled1 locationNCT07005180
Recruiting
Phase 1Phase 2
This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.
Parkinson Disease
iRegene Therapeutics Co., Ltd.5 enrolled1 locationNCT07102342
Recruiting
Phase 2
Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's Disease
DepressionParkinson DiseasePARKINSON DISEASE (Disorder)
University of British Columbia60 enrolled1 locationNCT05568498
Recruiting
Phase 2
Psilocybin Therapy for Psychological Distress in Palliative Patients
COPD, Chronic Obstructive Pulmonary DiseaseMajor Depressive Disorder (MDD)ALS (Amyotrophic Lateral Sclerosis)+2 more
University Medical Center Groningen108 enrolled4 locationsNCT06782724
Recruiting
Phase 1Phase 2
The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
Parkinson Disease
University of Alabama at Birmingham205 enrolled1 locationNCT03457493
Recruiting
Phase 2
Etoricoxib in Patients With Parkinsonian Disease
Parkinson Disease
Ihab Elsayed Hassan60 enrolled1 locationNCT07370532
Recruiting
Phase 2
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
Parkinson Disease
Appello Pharmaceuticals, Inc.150 enrolled25 locationsNCT07432958
Recruiting
Phase 2
Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease
Parkinson Disease
Vikas Kotagal102 enrolled1 locationNCT06679374
Recruiting
Phase 2
18F-mFBG Cardiac Uptake With Lewy Body Dementia
Lewy Body Dementia (LBD)Parkinson Disease (PD)
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)20 enrolled1 locationNCT07176286
Recruiting
Phase 2Phase 3
Montelukast in Parkinson Disease
Parkinson Disease
Mostafa Bahaa60 enrolled1 locationNCT06113640
Recruiting
Phase 1Phase 2
Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy
SafetyPARKINSON DISEASE (Disorder)Apathy
Integrative Research Laboratories AB75 enrolled13 locationsNCT07461220
Recruiting
Phase 2
Pyridostigmine for the Treatment of Constipation in Parkinson Disease
ConstipationParkinson Disease
University of Vermont Medical Center16 enrolled1 locationNCT05603715
Recruiting
Phase 2
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
Parkinson Disease
Denali Therapeutics Inc.50 enrolled20 locationsNCT06602193
Recruiting
Phase 1Phase 2
Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease.
Parkinson DiseaseOrthostatic Hypotension, DysautonomicMulti-system Atrophy - Parkinsonian Type
Julien Bally36 enrolled2 locationsNCT06831500
Recruiting
Phase 1Phase 2
Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms
PARKINSON DISEASE (Disorder)
U: The Mind Company30 enrolled1 locationNCT07182058